Annexon (ANNX) Total Non-Current Liabilities (2020)
Annexon's (ANNX) quarterly Total Non-Current Liabilities came in at $868000.0 in Q4 2020, up 230.53% quarter-over-quarter from -$665000.0 in Q3 2020.
Annexon (ANNX) Total Non-Current Liabilities (2020) Analysis & Trends
Annexon's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $868000.0 for Q4 2020.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $868000.0 in Q4 2020; TTM through Dec 2020 was $868000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $868000.0, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $868000.0 in Q4 2020 per ANNX's latest filing, from -$665000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $868000.0 in Q4 2020 and bottomed at -$665000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Annexon | 1.03 Bn | 804.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 868,000.00 |
| Sep 30, 2020 | -665,000.00 |